REPAGLINIDE
Cystic Fibrosis Related Diabetes
Arbelaez, Ana MariaSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Cystic Fibrosis Related Diabetes cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Glargine Insulin University of Minnesota | Phase 3 | BB |
Semaglutide University of Minnesota | Phase 2/3 | B |
Empagliflozin University of Minnesota | Phase 2/3 | B |
Insulin Detemir [Rdna Origin] Nationwide Children's Hospital | Phase 2/3 | CCC |
Metformin University of Kansas Medical Center | Phase 2 | CCC |
GLUCOSE, ANHYDROUS Children's Hospital of Philadelphia | Early Phase 1 | CCC |
Dorzagliatin University of Pennsylvania | Phase 1 | CC |
Same molecule, other indications
REPAGLINIDE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →